Effects of higher blood pressure on kidney function in patients with shock
Effects of Increasing Mean Arterial Pressure on Renal Function in Patients With Shock and With Elevated Central Venous Pressure : a Pilot Study for the Individualization of Mean Arterial Pressure
This study is testing if raising blood pressure helps improve kidney function in patients who are in shock.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Locations | 2 sites (Angers and 1 other locations) |
| Trial ID | NCT05655065 on ClinicalTrials.gov |
What this trial studies
This study evaluates how increasing mean arterial pressure (MAP) affects renal function in patients experiencing shock with elevated central venous pressure (CVP). Participants will be randomized to receive two different MAP targets (65-70 mmHg and 80-85 mmHg) over two consecutive 6-hour periods. The goal is to determine if optimizing renal perfusion pressure can improve kidney function in these patients. The study will measure renal function at the end of each period to assess the outcomes of the different MAP targets.
Who should consider this trial
Good fit: Ideal candidates include adults with arterial hypotension requiring catecholamines and high central venous pressure.
Not a fit: Patients with anuria or those requiring immediate renal replacement therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved kidney function and reduced risk of acute renal failure in patients with shock.
How similar studies have performed: While the approach of optimizing MAP in shock patients is explored, this specific methodology regarding CVP and renal function is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 18 years old ) * Arterial hypotension requiring the etablishment of catecholamines * Norepinephrine dose ⩾ 0.1µg/kg/min at the inclusion * High central venous pressure ≥ 12mmHg * Cardiac output monitoring (PICCO or Swan Ganz) Exclusion Criteria: * Anuria * Patient with an emergency indication of renal replacement therapy (severe hyperkalemia, severe metabolical acidosis with pH \<7.15, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration \> 40 mmol/l) * Pregnant, lactating or parturient woman * Patient deprived of liberty by judicial or administrative decision * Patient with psychiatric compulsory care * Patient subject to legal protection measures * Patients with do-no-reanimate order or withdrawal of life sustaining support
Where this trial is running
Angers and 1 other locations
- Angers University Hospital — Angers, France (Recruiting)
- Vendée Hospital — La Roche-sur-Yon, France (Recruiting)
Study contacts
- Principal investigator: Pierre ASFAR, MD PhD — University Hospital, Angers
- Study coordinator: Nicolas FAGE, MD
- Email: nicolas.fage@chu-angers.fr
- Phone: +332 41 35 36 37
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.